Tag Archives: India

Novartis at India Supreme Court: Evergreening Myths and Patent Reality

Pine

Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec.  The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening. 1.  Patent “Ever-Greening”: Novartis Confronts Patent Myth in India 2.  Patent Evergreening in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Spotlight on India’s Emerging Biotech Sector

india-flag

India’s biotechnology sector is a burgeoning one, with more than 325 companies and some with revenues in the billions of dollars. According to the BioSpectrum-ABLE (Association of Biotechnology Led Enterprises) Biotech Industry Survey of 2011, the industry has grown by 21.5% in 2006-2011, surging to $4 billion. Furthermore, India is the world’s largest manufacturer of vaccines and the growth of India vaccine makers arises from their ability to develop and produce high-quality vaccines with low Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2012 BIO India International Conference: Top Five Reasons to Attend

biocon

The third annual BIO India International Conference will be held September 12-13 at the Grand Hyatt in Mumbai, India. BIO India will feature high-level keynote speakers, education panels on the latest trends, networking opportunities, company presentations and partnering meeting opportunities through the BIO One-on-One Partnering™ system. The event is particularly relevant and timely for those looking to learn more about India’s rapidly growing global presence in the life sciences. Read more to learn the top Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Patent Evergreening in India: Response from the Other Side

Plant

Thank you Adriana for commenting on my article Patent “Ever-Greening”: Novartis Confronts Patent Myth in India.  Before I respond, here is your full comment: Adriana says: While patients in India may still be able to access a generic form of off-patent imatinib mesylate (Glivec) if Novartis wins their legal challenge (because this “original form” was never patented in India due to India’s patent law not allowing product patents on medicines prior to 2005), a legal Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

India Compulsory License: A Times of India Article Says It’s Not Helping the Poor

india-btn

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with the stated goal of providing access to India’s poor. However, the Times of India recently ran the article Cheap generics drugs no panacea for India’s poorest, quickly dispelling this myth: “The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA), India’s drug Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,